Health Care [ 2/12 ] | Pharmaceuticals [ 6/73 ]
NASDAQ | Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation.
The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity.
Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -0.66 | -0.68 Increased by +2.60% |
| May 14, 25 | -0.71 | -0.70 Decreased by -1.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -14.37 M Decreased by -163.66% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -9.31 M Decreased by -327.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -8.78 M Decreased by -330.13% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -4.18 M Decreased by -98.29% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 - | -5.45 M - | Decreased by N/A% - |
| Mar 31, 24 | 0.00 - | -2.18 M - | Decreased by N/A% - |
| Dec 31, 23 | 0.00 - | -2.04 M - | Decreased by N/A% - |
| Sep 30, 23 | 0.00 - | -2.11 M - | Decreased by N/A% - |